The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
June 18th 2025
In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.
Elimination of Long-Term Opioid Therapy Found to Stabilize or Reduce Chronic PainÂ
July 16th 2018The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.
Read More
FDA Approves Immuno-Oncology Combination for Metastatic Colorectal Cancer
July 12th 2018Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read More
Olaparib Delays Disease Progression as First-Line Treatment in Advanced Ovarian Cancer
July 12th 2018Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.
Read More
Breast Cancer Treatment Combo Falls Short of Overall Survival Goal
July 10th 2018The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Read More